JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265503

Human NDUFA2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

NDUFA2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 2 bp deletion in exon 1.

View Alternative Names

B8, CI-B8, Complex I-B8, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 2, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 2 8kDa, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2, NADH-ubiquinone oxidoreductase B8 subunit, NDUA2_HUMAN

2 Images
Sanger Sequencing - Human NDUFA2 knockout HeLa cell line (AB265503)
  • Sanger seq

Unknown

Sanger Sequencing - Human NDUFA2 knockout HeLa cell line (AB265503)

Allele-2 : 1 bp deletion in exon 1.

Sanger Sequencing - Human NDUFA2 knockout HeLa cell line (AB265503)
  • Sanger seq

Unknown

Sanger Sequencing - Human NDUFA2 knockout HeLa cell line (AB265503)

Allele-1 : 2 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 2 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265503-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265503 Human NDUFA2 knockout HeLa cell line", "number":"AB265503-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265503-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265503 Human NDUFA2 knockout HeLa cell line", "number":"AB265503-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
NDUFA2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The NDUFA2 protein also known as NADH:Ubiquinone Oxidoreductase Subunit A2 is a component of the mitochondrial respiratory chain complex I. It has a mass of approximately 10.3 kDa. NDUFA2 is expressed in various tissues with high energy demands especially in the heart brain and skeletal muscles. Functionally it participates in the initial phase of electron transport by transferring electrons from NADH to ubiquinone contributing to the proton gradient used in ATP synthesis.
Biological function summary

NDUFA2 is a component of the multi-subunit complex I of the mitochondrial electron transport chain. This complex plays a role in cellular respiration by facilitating the conversion of energy stored in nutrients into ATP. Within the structure of complex I NDUFA2 collaborates with other subunits to ensure efficient electron transfer processes. Although a smaller subunit its role in the proper assembly and maintenance of the complex is essential for sustaining cellular energy levels.

Pathways

The actions of NDUFA2 are critical in oxidative phosphorylation one of the main pathways for ATP production in eukaryotic cells. This energy production pathway is intertwined with cellular respiration where NDUFA2 is related to proteins such as ND1 and ND2. These proteins collectively engage in the transfer of electrons across the inner mitochondrial membrane driving the synthesis of ATP from ADP through chemiosmotic coupling.

Alterations in NDUFA2 have connections to mitochondrial encephalomyopathy and Leigh Syndrome. These conditions manifest due to dysfunctional energy metabolism caused by defects in NDUFA2 and other proteins like NDUFS1. Mutations in these proteins can lead to impaired oxidative phosphorylation resulting in energy deficiencies that contribute to the development of neurodegenerative and muscular impairments seen in these disorders.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com